The Promising Role of Monoclonal Antibodies for Immunotherapy of the Hiv-Associated Cancer, Non-Hodgkin Lymphoma Publisher Pubmed



Rezahosseini O^{1, 2} ; Hanaei S^{1, 3, 4} ; Hamadani M^{5, 6} ; Keshavarzfathi M^{1, 3, 4, 7} ; Rezaei N^{3, 8, 9} Show Affiliations
Source: International Reviews of Immunology Published:2018

Abstract

Association between HIV/AIDS and some of the cancers such as lymphomais is well known. Relative risk for developing non-Hodgkin lymphoma (NHL) increases 60–200 folds in HIV-infected individuals. Diffuse large B cell lymphoma (DLBCL), primary effusion lymphoma (PEL), Burkitt's lymphoma (BL) and Plasmablastic Lymphoma (PBL) are among the most frequent subtypes. During the last century, scientists found that the immune system could potentially detect and destroy cancer cells. Therefore, they started a new field of study, which is named immunotherapy. There are different immunotherapeutic methods, among which therapeutic antibodies, such as Brentuximabvedotin (Adcetris), Ibritumomabtiuxetan (Zevalin) and rituximab (Rituxan), used for treatment of NHLs showed promising results. In this article, we will review the immunotherapeutic option, monoclonal antibodies, for treatment of HIV-associated NHLs as well as their recent clinical status. We will also discuss the selective monoclonal antibody for each subtype of NHLs. © 2018 Taylor & Francis.